Floatz logo

Entacapone

Brain Diseases

Merck Sharp & Dohme LLCSmall moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
81/ 100

Competitive context

24 Active assets in the Brain Diseases cohort.

Asset / SponsorPhaseRating
Galantamine Hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3B
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4B
Fremanezumab
Hospital Clínico Universitario de Valladolid
Phase 4B
Donanemab
Eli Lilly and Company
Phase 3B
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4B

View all 42 →

Same molecule, other indications

Entacapone is also rated in:

Parkinson diseaseDormant
BBB
Indicative ·
74 / 100
View asset →
Neurodegenerative DiseasesDormant
B
Indicative ·
62 / 100
View asset →
Central Nervous System DiseasesDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →